Vicore Pharma and Nippon Shinyaku have signed an exclusive licensing agreement for the development and commercialization of the former’s C21 for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan
As per the agreement, Vicore retains all the global rights (excl. Japan) to C21 & will obtain $10M upfront, a total of $275M milestones for development and commercialization plus low 20s annual net sales-based tiered royalties while Nippon Shinyaku receives exclusive development & commercialization rights in Japan
Additionally, the company’s P-IIa (AIR) trial revealed improvement in lung function with C21 in previously untreated IPF patients. A global P-IIb (ASPIRE) study is anticipated in H1’24
Ref: Vicore | Image: Vicore
Related Newswire:- Capricor Entered into an Exclusive Commercialization and Distribution Agreement with Nippon Shinyaku for CAP-1002 to Treat Duchenne Muscular Dystrophy in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
